Q3 EPS Estimates for Prime Medicine Cut by HC Wainwright

Key Points

• HC Wainwright has cut its Q3 2025 earnings per share (EPS) estimate for Prime Medicine to ($0.33) from ($0.31) and maintains a "Neutral" rating on the stock.
• Consensus estimates now suggest Prime Medicine will incur a full-year EPS loss of ($1.68) with ongoing losses projected through FY2029.
• Despite recent price target cuts from various analysts, the consensus rating for Prime Medicine remains a "Moderate Buy" with a target price of $8.92.

Prime Medicine, Inc. (NYSE:PRME - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2025 EPS estimates for Prime Medicine in a research report issued to clients and investors on Monday, August 11th. HC Wainwright analyst A. He now expects that the company will earn ($0.33) per share for the quarter, down from their previous estimate of ($0.31). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Prime Medicine's current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Prime Medicine's Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.45) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.51) EPS, FY2027 earnings at ($1.51) EPS, FY2028 earnings at ($1.27) EPS and FY2029 earnings at ($1.00) EPS.

Several other brokerages also recently issued reports on PRME. Chardan Capital cut their price objective on Prime Medicine from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Citigroup restated a "neutral" rating and set a $1.50 price objective (down from $10.00) on shares of Prime Medicine in a research report on Tuesday, May 27th. Wedbush restated an "outperform" rating and set a $8.00 price objective on shares of Prime Medicine in a research report on Wednesday, July 16th. JPMorgan Chase & Co. restated a "neutral" rating on shares of Prime Medicine in a research report on Tuesday, May 20th. Finally, JMP Securities cut their price objective on Prime Medicine from $10.00 to $6.00 and set a "market outperform" rating for the company in a research report on Tuesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Prime Medicine has a consensus rating of "Moderate Buy" and a consensus target price of $8.92.

Prime Medicine Price Performance

Prime Medicine stock traded down $0.2650 during mid-day trading on Thursday, reaching $3.2350. The company had a trading volume of 2,901,370 shares, compared to its average volume of 2,514,182. Prime Medicine has a 1 year low of $1.11 and a 1 year high of $5.17. The company has a market capitalization of $435.35 million, a P/E ratio of -1.57 and a beta of 2.39. The stock's 50-day simple moving average is $3.36 and its 200-day simple moving average is $2.36.

Insider Buying and Selling at Prime Medicine

In other Prime Medicine news, major shareholder David R. Liu purchased 21,000 shares of the firm's stock in a transaction that occurred on Monday, June 23rd. The stock was purchased at an average cost of $2.16 per share, with a total value of $45,360.00. Following the transaction, the insider owned 20,219,945 shares in the company, valued at approximately $43,675,081.20. This trade represents a 0.10% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Arch Venture Partners Xii, Llc purchased 3,030,300 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were acquired at an average cost of $3.30 per share, with a total value of $9,999,990.00. Following the completion of the transaction, the insider owned 6,230,300 shares in the company, valued at $20,559,990. This trade represents a 94.70% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 3,093,300 shares of company stock valued at $10,110,240 over the last three months. Corporate insiders own 22.74% of the company's stock.

Hedge Funds Weigh In On Prime Medicine

A number of institutional investors have recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC bought a new position in shares of Prime Medicine during the second quarter worth about $531,000. Bank of America Corp DE lifted its position in shares of Prime Medicine by 28.0% during the second quarter. Bank of America Corp DE now owns 144,511 shares of the company's stock worth $357,000 after purchasing an additional 31,585 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Prime Medicine by 253.4% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 119,856 shares of the company's stock worth $296,000 after purchasing an additional 85,938 shares during the last quarter. Diametric Capital LP bought a new position in shares of Prime Medicine during the second quarter worth about $261,000. Finally, Greenwich Wealth Management LLC lifted its position in shares of Prime Medicine by 3.3% during the second quarter. Greenwich Wealth Management LLC now owns 846,201 shares of the company's stock worth $2,090,000 after purchasing an additional 27,200 shares during the last quarter. Institutional investors and hedge funds own 70.37% of the company's stock.

About Prime Medicine

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.